Malin Corporation | MLC - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alaunos Therapeutics USD 1.01M 175K 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Avita Medical AUD 28.02M 1.55M 2025-12
Dianthus Therapeutics USD 47M 22.83M 2026-03
Eurofins Scientific SE EUR 3.2B 91.8M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
IQVIA Holdings USD 1.77B 4.45B 2026-06
Lonza CHF 2.9B 184M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Moderna USD 960M 817M 2026-06
Organon & Co USD 903M 387M 2026-03
Ovoca Bio EUR 173K 990K 2025-12
Revvity USD 603.55M 24.8M 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Viatris USD 3.54B 323.9M 2026-03
Xeris Pharmaceuticals USD 75.21M 6.18M 2026-03